DNA Vaccine May Stop MS
In Early Test, Multiple Sclerosis Vaccine Turns off Harmful Immune Response
WebMD News Archive
Aug. 13, 2007 - A new kind of vaccine promises to halt the destructive
immune responses behind multiple sclerosis, type 1 diabetes, and other
Thirty patients already have received four injections of the MS version of
the vaccine in a phase 1 clinical trial. The vaccine was very safe, at least in
the short term. And there was tantalizing evidence that it just might work.
Hideki Garren, MD, PhD, is one of four Stanford University researchers who
invented the vaccine and co-founded Bayhill Therapeutics to develop it. Garren
notes that MS is an autoimmune disease in which a specific kind of immune cells
-- T cells -- attack nerve
"Our vaccine is designed to go only after the disease-causing cells in
MS and leave the other T cells alone," Garren, now Bayhill's vice president
of research, tells WebMD. "The first advantage of this approach is we
should have fewer side effects than current MS drugs. And second, this should
modify the underlying disease because we are going after the disease-causing
In MS patients, T cells attack the myelin sheath that protects nerve fibers. One of the T cells targets
is a specific myelin protein -- an antigen -- called myelin basic protein
The new vaccine is made of genetically engineered DNA that encodes MBP.
Normal vaccines provoke immune responses against the antigens in the vaccine.
But the Bayhill vaccine attaches the MBP DNA to a "backbone" cleverly
designed to turn off immune responses instead of turning them on.
Sure enough, the vaccine did not make any of the patients' MS worse. In
fact, MRI scans suggested that the treated patients had fewer MS brain lesions
than those who got inactive placebo shots.
"We did see a trend in reduction of lesions," Garren says. "But
these are just trends. Certainly this needs to be tested in larger
Garren's team has just completed a phase II trial in which 290 patients
received 13 doses of the vaccine over one year. They plan to report the results
in October at a large European MS conference.